137 related articles for article (PubMed ID: 36583936)
1. Pulmonary Administration of the Liposome-Based Adjuvant CAF01: Effect of Surface Charge on Mucosal Adjuvant Function.
Müllertz OAO; Andersen P; Christensen D; Foged C; Thakur A
Mol Pharm; 2023 Feb; 20(2):953-970. PubMed ID: 36583936
[TBL] [Abstract][Full Text] [Related]
2. Intrapulmonary (i.pulmon.) Pull Immunization With the Tuberculosis Subunit Vaccine Candidate H56/CAF01 After Intramuscular (i.m.) Priming Elicits a Distinct Innate Myeloid Response and Activation of Antigen-Presenting Cells Than i.m. or i.pulmon. Prime Immunization Alone.
Thakur A; Pinto FE; Hansen HS; Andersen P; Christensen D; Janfelt C; Foged C
Front Immunol; 2020; 11():803. PubMed ID: 32457748
[TBL] [Abstract][Full Text] [Related]
3. Toll like-receptor agonist Pam
Kennerknecht K; Noschka R; Löffler F; Wehrstedt S; Pedersen GK; Mayer D; Grieshober M; Christensen D; Stenger S
Med Microbiol Immunol; 2020 Apr; 209(2):163-176. PubMed ID: 32020284
[TBL] [Abstract][Full Text] [Related]
4. Dual-Isotope SPECT/CT Imaging of the Tuberculosis Subunit Vaccine H56/CAF01: Induction of Strong Systemic and Mucosal IgA and T-Cell Responses in Mice Upon Subcutaneous Prime and Intrapulmonary Boost Immunization.
Thakur A; Rodríguez-Rodríguez C; Saatchi K; Rose F; Esposito T; Nosrati Z; Andersen P; Christensen D; Häfeli UO; Foged C
Front Immunol; 2018; 9():2825. PubMed ID: 30555488
[TBL] [Abstract][Full Text] [Related]
5. Lipid conjugation of TLR7 agonist Resiquimod ensures co-delivery with the liposomal Cationic Adjuvant Formulation 01 (CAF01) but does not enhance immunopotentiation compared to non-conjugated Resiquimod+CAF01.
Wilkinson A; Lattmann E; Roces CB; Pedersen GK; Christensen D; Perrie Y
J Control Release; 2018 Dec; 291():1-10. PubMed ID: 30291987
[TBL] [Abstract][Full Text] [Related]
6. Designing CAF-adjuvanted dry powder vaccines: spray drying preserves the adjuvant activity of CAF01.
Ingvarsson PT; Schmidt ST; Christensen D; Larsen NB; Hinrichs WL; Andersen P; Rantanen J; Nielsen HM; Yang M; Foged C
J Control Release; 2013 May; 167(3):256-64. PubMed ID: 23415813
[TBL] [Abstract][Full Text] [Related]
7. Elucidating the mechanisms of protein antigen adsorption to the CAF/NAF liposomal vaccine adjuvant systems: effect of charge, fluidity and antigen-to-lipid ratio.
Hamborg M; Rose F; Jorgensen L; Bjorklund K; Pedersen HB; Christensen D; Foged C
Biochim Biophys Acta; 2014 Aug; 1838(8):2001-10. PubMed ID: 24769435
[TBL] [Abstract][Full Text] [Related]
8. Method of manufacturing CAF®09 liposomes affects immune responses induced by adjuvanted subunit proteins.
Thakur A; Wadhwa A; Lokras A; Müllertz OAO; Christensen D; Franzyk H; Foged C
Eur J Pharm Biopharm; 2023 Aug; 189():84-97. PubMed ID: 37059402
[TBL] [Abstract][Full Text] [Related]
9. The surface charge of liposomal adjuvants is decisive for their interactions with the Calu-3 and A549 airway epithelial cell culture models.
Ingvarsson PT; Rasmussen IS; Viaene M; Irlik PJ; Nielsen HM; Foged C
Eur J Pharm Biopharm; 2014 Aug; 87(3):480-8. PubMed ID: 24726978
[TBL] [Abstract][Full Text] [Related]
10. Immunological and physical evaluation of the multistage tuberculosis subunit vaccine candidate H56/CAF01 formulated as a spray-dried powder.
Thakur A; Ingvarsson PT; Schmidt ST; Rose F; Andersen P; Christensen D; Foged C
Vaccine; 2018 May; 36(23):3331-3339. PubMed ID: 29699790
[TBL] [Abstract][Full Text] [Related]
11. Transcriptomics of the Vaccine Immune Response: Priming With Adjuvant Modulates Recall Innate Responses After Boosting.
Santoro F; Pettini E; Kazmin D; Ciabattini A; Fiorino F; Gilfillan GD; Evenroed IM; Andersen P; Pozzi G; Medaglini D
Front Immunol; 2018; 9():1248. PubMed ID: 29922291
[TBL] [Abstract][Full Text] [Related]
12. Immunity by formulation design: induction of high CD8+ T-cell responses by poly(I:C) incorporated into the CAF01 adjuvant via a double emulsion method.
Nordly P; Rose F; Christensen D; Nielsen HM; Andersen P; Agger EM; Foged C
J Control Release; 2011 Mar; 150(3):307-17. PubMed ID: 21111765
[TBL] [Abstract][Full Text] [Related]
13. Design of Gadoteridol-Loaded Cationic Liposomal Adjuvant CAF01 for MRI of Lung Deposition of Intrapulmonary Administered Particles.
Thakur A; Rose F; Ansari SR; Koch P; Martini V; Ovesen SL; Quistorff B; Maritim S; Hyder F; Andersen P; Christensen D; Mori Y; Foged C
Mol Pharm; 2019 Nov; 16(11):4725-4737. PubMed ID: 31539263
[TBL] [Abstract][Full Text] [Related]
14. Comparison of two different PEGylation strategies for the liposomal adjuvant CAF09: Towards induction of CTL responses upon subcutaneous vaccine administration.
Schmidt ST; Olsen CL; Franzyk H; Wørzner K; Korsholm KS; Rades T; Andersen P; Foged C; Christensen D
Eur J Pharm Biopharm; 2019 Jul; 140():29-39. PubMed ID: 31055066
[TBL] [Abstract][Full Text] [Related]
15. Combinational PRR Agonists in Liposomal Adjuvant Enhances Immunogenicity and Protective Efficacy in a Tuberculosis Subunit Vaccine.
Hao L; Wu Y; Zhang Y; Zhou Z; Lei Q; Ullah N; Banga Ndzouboukou JL; Lin X; Fan X
Front Immunol; 2020; 11():575504. PubMed ID: 33117374
[TBL] [Abstract][Full Text] [Related]
16. Th1 immune responses can be modulated by varying dimethyldioctadecylammonium and distearoyl-sn-glycero-3-phosphocholine content in liposomal adjuvants.
Hussain MJ; Wilkinson A; Bramwell VW; Christensen D; Perrie Y
J Pharm Pharmacol; 2014 Mar; 66(3):358-66. PubMed ID: 24251796
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic Vaccination with Cationic Liposomes Formulated with Dioctadecyldimethylammonium and Trehalose Dibehenate (CAF01) and Peptide P10 Is Protective in Mice Infected with
Araújo MV; Santos Júnior SRD; Nosanchuk JD; Taborda CP
J Fungi (Basel); 2020 Dec; 6(4):. PubMed ID: 33302372
[TBL] [Abstract][Full Text] [Related]
18. Adsorption of protein antigen to the cationic liposome adjuvant CAF®01 is required for induction of Th1 and Th17 responses but not for antibody induction.
Wørzner K; Hvannastein J; Schmidt ST; Foged C; Rosenkrands I; Pedersen GK; Christensen D
Eur J Pharm Biopharm; 2021 Aug; 165():293-305. PubMed ID: 34044110
[TBL] [Abstract][Full Text] [Related]
19. Influence of trehalose 6,6'-diester (TDX) chain length on the physicochemical and immunopotentiating properties of DDA/TDX liposomes.
Kallerup RS; Madsen CM; Schiøth ML; Franzyk H; Rose F; Christensen D; Korsholm KS; Foged C
Eur J Pharm Biopharm; 2015 Feb; 90():80-9. PubMed ID: 25445301
[TBL] [Abstract][Full Text] [Related]
20. The vesicle size of DDA:TDB liposomal adjuvants plays a role in the cell-mediated immune response but has no significant effect on antibody production.
Henriksen-Lacey M; Devitt A; Perrie Y
J Control Release; 2011 Sep; 154(2):131-7. PubMed ID: 21640145
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
